A Prospective Randomized Double Blind Phase 3 Clinical Trial of Anti- T Lymphocyte Globulin (ATLG) to Assess Impact on Chronic Graft-Versus-Host Disease (cGVHD) Free Survival in Patients Undergoing HLA Matched Unrelated Myeloablative Hematopoietic Cell Transplantation (HCT)
Year: 2016
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: Blood
Authors: Robert J. Soiffer, Haesook T. Kim, Joseph McGuirk, Mitchell E. Horwitz, Laura Johnston, Mrinal M Patnaik, Witold Rybka, Andrew Artz, David L Porter, Thomas C. Shea, Michael W Boyer, Richard T. Maziarz, Madan H. Jagasia, Paul J. Shaughnessy, Usama Gergis, Hana Safah, Ran Reshef, John F. DiPersio, Patrick J. Stiff, Madhuri Vusirikala, Jeff Szer, Jennifer Holter, James D. Levine, Paul J. Martin, Joseph A. Pidala, Ian D. Lewis, Vincent T. Ho, Edwin P. Alyea, Jerome Ritz, Frank Glavin, Peter Westervelt, Yi-Bin Chen
Institutions: Dana-Farber Cancer Institute, University of Kansas Medical Center, Duke Medical Center, Stanford Medicine, Stanford University, Mayo Clinic, Penn State Cancer Institute, University of Chicago, University of Pennsylvania, University of North Carolina at Chapel Hill, University of North Carolina Health Care, University of Utah, Oregon Health & Science University, OHSU Knight Cancer Institute, Vanderbilt University Medical Center, Cornell University, Weill Cornell Medicine, Tulane University, Columbia University Irving Medical Center, Washington University in St. Louis, Loyola University Medical Center, Loyola University Chicago, Loyola Medicine, The University of Texas Southwestern Medical Center, The Royal Melbourne Hospital, University of Oklahoma Health Sciences Center, Beth Israel Deaconess Medical Center, Harvard University, Fred Hutch Cancer Center, Moffitt Cancer Center, Royal Adelaide Hospital, Massachusetts General Hospital
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2591079751